Tectonic Therapeutic, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Alise S. Reicin
- Full Time Employees
- 60
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 490 Arsenal Way Watertown MA United States of America 02472
- IPO Date
- Jun 21, 2018
- CIK
- 0001681087
- Website
- tectonictx.com
- Similar Companies
- Business
- Tectonic Therapeutic, Inc. is a clinical-stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs). The company utilizes its proprietary GEODe™ technology platform, which enables the discovery and development of GPCR-targeted biologic medicines designed to address significant unmet medical needs, particularly in areas where therapeutic options are limited or nonexistent. Tectonic’s product pipeline includes RXFP1 agonists in Phase 1a and 1b clinical trials for heart failure with preserved ejection fraction; a GPCR antagonist targeting hereditary hemorrhagic telangiectasia; and bi-functional GPCR modulators aimed at fibrosis and other indications. The company operates primarily in the United States and is headquartered in Watertown, Massachusetts. In terms of recent developments, Tectonic Therapeutic completed a reverse merger with gene therapy company AVROBIO in June 2024, which was accompanied by $130.7 million in private placement financing from a syndicate of leading life sciences investors. This merger expanded Tectonic's financial resources and operational capabilities, with the combined entity continuing under the Tectonic Therapeutic name and trading on Nasdaq under the ticker symbol TECX. Additionally, in July 2024, the company secured U.S. FDA IND approval for its lead candidate, TX45, advancing it into Phase 2 clinical trials for pulmonary hypertension associated with heart failure. Tectonic's strategic focus remains on developing novel biologics for diseases with substantial unmet needs by leveraging its GEODe platform to overcome traditional drug discovery challenges in GPCR biology. Tectonic Therapeutic targets the biotechnology and pharmaceutical industry segments, serving patient populations with rare and difficult-to-treat conditions. Its biologic drug candidates focus on modulating GPCRs, a large family of receptors critical in numerous physiological processes, which represent a significant frontier in therapeutic development. The company’s comprehensive approach combines innovative protein engineering with clinical-stage development programs, reinforcing its position as an emerging leader in GPCR-targeted therapies. Founded in 2017, Tectonic Therapeutic continues to navigate clinical and regulatory milestones while expanding its product pipeline and investor engagement within the biotechnology sector.
Company News
Tectonic Therapeutic Announces Favorable Phase 1 Safety, Tolerability and PK Results for TX2100, a Novel Approach for the Treatment of Hereditary Hemorrhagic Telangiectasia (HHT)
Tectonic Therapeutic, Inc. (NASDAQ:TECX) Stock Has Average Price Target of $77.25 According to Analysts
Tectonic Therapeutic to Participate in the Morgan Stanley Global Healthcare Conference
Tectonic Therapeutic: Competitor Data Strengthens The TX45 Bull Case
Tectonic Therapeutic Announces Second Quarter 2026 Financial Results and Recent Business Highlights
Tectonic Therapeutic Completes Enrollment in TX45 APEX Phase 2 Clinical Trial in PH-HFpEF Patients
Tectonic Therapeutic Completes Enrollment in TX45 APEX Phase 2 Clinical Trial in PH-HFpEF Patients
Tectonic Therapeutic Announces First Quarter 2026 Financial Results and Recent Business Highlights
Tectonic Therapeutic Appoints Jessica Chutter to Board of Directors
Tectonic Therapeutic: A $1B+ Opportunity Hinges On Upcoming Phase 2
Tectonic Therapeutic, Inc. (NASDAQ:TECX) Receives $81.50 Consensus Price Target from Analysts
Aberdeen Group plc Acquires 785,648 Shares of Tectonic Therapeutic, Inc. $TECX
Tectonic Therapeutic, Inc. $TECX Shares Sold by Ally Bridge Group NY LLC
Tectonic Therapeutic, Inc. (NASDAQ:TECX) Receives Average Recommendation of “Moderate Buy” from Brokerages
Tectonic Therapeutic, Inc. (TECX) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Tectonic Therapeutic Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
Tectonic Therapeutic Appoints François Nader, M.D., as Chair and Independent Director of the Board
Tectonic Therapeutic to Host Virtual KOL Event and Discussion of TX2100, a Novel Approach for the Treatment of Hereditary Hemorrhagic Telangiectasia, on February 24, 2026
Tiziana Life Sciences (NASDAQ:TLSA) vs. Tectonic Therapeutic (NASDAQ:TECX) Financial Comparison
Tectonic Therapeutic, Inc. (NASDAQ:TECX) Receives $82.17 Average Target Price from Brokerages